Maxim Group analyst Jason McCarthy maintained a Buy rating on VistaGen Therapeutics (VTGN) yesterday and set a price target of $4. The company’s shares closed last Monday at $0.51, close to its 52-week low of $0.38.
McCarthy said:
“VistaGen reported F1Q20 results with a net loss of ($6.2M) and ended the period with $8.3M in cash on the balance sheet.”
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -24.1% and a 21.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Hancock Jaffe Laboratories Inc, and Aridis Pharmaceuticals Inc.
VistaGen Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.35.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.44 and a one-year low of $0.38. Currently, VistaGen Therapeutics has an average volume of 273.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
